Expression of antigens in B-cell lineage ALL for potential antibody therapy
| Surface antigen . | ALL subtype . | Expression (%) . | MoAb . |
|---|---|---|---|
| CD20 | Mature B-cell precursor | 86-100 30-40 | Rituximab, ofatumumab, obinituzumab |
| CD19 | Mature B-cell precursor | 95-<100 95-<100 | Blinatumomab |
| CD22 | Mature B-cell precursor | ∼100 93-98 | Inotuzumab ozogamicin, epratuzumab, moxetumomab pasudotox |
| Surface antigen . | ALL subtype . | Expression (%) . | MoAb . |
|---|---|---|---|
| CD20 | Mature B-cell precursor | 86-100 30-40 | Rituximab, ofatumumab, obinituzumab |
| CD19 | Mature B-cell precursor | 95-<100 95-<100 | Blinatumomab |
| CD22 | Mature B-cell precursor | ∼100 93-98 | Inotuzumab ozogamicin, epratuzumab, moxetumomab pasudotox |
Adapted from Jabbour et al.2